Hagens Berman Advises Investors of May 13, 2014, Deadline in Geron Corporation Securities Lawsuit and Investigation

  Hagens Berman Advises Investors of May 13, 2014, Deadline in Geron   Corporation Securities Lawsuit and Investigation  Business Wire  BERKELEY, Calif. -- March 31, 2014  Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, is investigating Geron Corporation (NASDAQ: GERN) (“Geron” or “the Company”) for securities fraud following allegations that the company distributed false and misleading statements to investors concerning its business and prospects, and advises investors of the class-action lead plaintiff deadline on May 13, 2014. Investors who have suffered significant financial losses, and who want to discuss their options, can contact a Hagens Berman attorney by emailing Geron@hbsslaw.com.  The securities fraud class-action lawsuit, filed on March 14, 2014, on behalf of investors who purchased Geron stock between June 16, 2013 and March 11, 2014 (the “Class Period”), alleges that the company failed to disclose key information to its investors regarding halting of its sponsored clinical trials by the FDA.  For more information about the suit, please contact Hagens Berman Partner Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000. Additional information is available at http://hb-securities.com/investigations/Geron.  The complaint alleges that Geron, a clinical stage biopharmaceutical company, misrepresented or failed to disclose that persistent low-grade liver function test (LFT) abnormalities had been observed in the study of imetelstat – the company’s sole product candidate. According to the complaint, the company received notice from the FDA on March 12, 2014, that its work with imetelstat had been placed on full clinical hold, greatly affecting Geron’s sponsored clinical trials; Geron failed to disclose this information to investors. This hold was due to the potential risk of chronic liver injury following long-term exposure to imetelstat. Following this news, Geron shares declined $2.71 per share, more than 61 percent, to close at $1.69 per share on March 12, 2014.  “We believe that Geron did not adequately disclose the existence of persistent low-grade liver function tests and the concerns this raised about their prospects,” said Mr. Kathrein. “While Geron may have hoped that the FDA would not take action, the company has admitted that it was sufficiently concerned about the occurrence of these abnormalities that the company discussed the issue with its expert panel.”  The deadline to file for lead plaintiff in a recently filed securities fraud class action is May 13, 2014.  Persons with non-public information regarding Geron should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC Whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.  About Hagens Berman  Hagens Berman Sobol Shapiro LLP is an investor-rights class-action law firm with offices in nine cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the law firm and its successes can be found at www.hb-securities.com. Read the Firm’s Securities Newsletter at http://www.hb-securities.com/newsletter. The firm’s blog is located at www.meaningfuldisclosure.com.  Contact:  Firmani + Associates Mark Firmani, 206-443-9357 mark@firmani.com